Long-TermResponse to Intermittent Binimetinib in Patients withNRAS-Mutant Melanoma

Matter, AV; Micaletto, S; Urner-Bloch, U; Dummer, R; Goldinger, SM

Dummer, R (corresponding author), Univ Hosp Zurich, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.

ONCOLOGIST, 2020; 25 (11): E1593

Abstract

Melanoma can be classified based on the detection of relevant oncogenic driver mutations. These mutations partially determine a patient's treatment op......

Full Text Link